Home page Home page
AstraZeneca

Purevax FeLV
vaccine against feline leukaemia


PACKAGE LEAFLET:

Purevax FeLV suspension for injection


  1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT


    Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein

    GERMANY


    Manufacturing authorisation holder responsible for batch release Boehringer Ingelheim Animal Health France SCS

    Laboratoire Porte des Alpes Rue de l’Aviation

    69800 SAINT PRIEST FRANCE


  2. NAME OF THE VETERINARY MEDICINAL PRODUCT


    Purevax FeLV suspension for injection


  3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)


    Each dose of 1 ml or 0.5ml contains:


    Active substance:

    FeLV recombinant Canarypox virus (vCP97) ................................................. ≥ 10 7.2 CCID501

    1cell culture infective dose 50%


    Clear colourless liquid with presence of cell debris in suspension.


  4. INDICATION(S)


    Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

    Onset of immunity: 2 weeks after primary vaccination course. Duration of immunity: 1 year after the last vaccination.


  5. CONTRAINDICATIONS


    None.


  6. ADVERSE REACTIONS


    A temporary small (< 2 cm) nodule, which regresses within 1 to 4 weeks, was very commonly observed at the site of injection during safety and field studies.

    Transient lethargy and hyperthermia were very commonly observed during safety and field studies and lasted usually for 1 day, exceptionally for 2 days.

    Anorexia and emesis have been reported very rarely based on post marketing safety experience.

    A hypersensitivity reaction may occur in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis). If such reactions occur, appropriate treatment is recommended.


    The frequency of adverse reactions is defined using the following convention:

    • very common (more than 1 in 10 animals treated displaying adverse reaction(s))

    • common (more than 1 but less than 10 animals treated in 100 animals)

    • uncommon (more than 1 but less than 10 animals treated in 1,000 animals )

    • rare (more than 1 but less than 10 animals in 10,000 animals treated)

    • very rare (less than 1 animal in 10,000 animals treated, including isolated reports).


    If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.


  7. TARGET SPECIES


    Cats.


  8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION


    Subcutaneous use.


    Administer one dose of 1ml or 0.5 ml of vaccine (depending on the presentation chosen) according to the following schedule:


    Basic vaccination: first injection: from 8 weeks of age,

    second injection: 3 to 5 weeks later.

    Revaccination: annual


  9. ADVICE ON CORRECT ADMINISTRATION


    Shake well before use.


  10. WITHDRAWAL PERIOD(S)


    Not applicable


  11. SPECIAL STORAGE PRECAUTIONS


    Keep out of the sight and reach of children. Store and transport refrigerated (2°C – 8°C),

    Protect

    from light. Do not freeze.

    Shelf life after broaching: use immediately.

    Do not use this veterinary medicinal product after the expiry date, which is stated on the label after EXP.

  12. SPECIAL WARNING(S)


    Special warnings for each target species: Vaccinate healthy animals only.


    Special precautions for use in animals:

    It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit.


    Special precautions to be taken by the person administering the veterinary medicinal product to animals:

    In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.


    Pregnancy and lactation:

    Do not use during the whole pregnancy and lactation.


    Interaction with other medicinal products and other forms of interaction:

    Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Boehringer Ingelheim non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/or administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies.

    No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.


    Overdose (symptoms, emergency procedures, antidotes):

    No other effect has been observed except those mentioned in the “Adverse reactions” section.


    Incompatibilities:

    Do not mix with any other vaccine or immunological product except Boehringer Ingelheim non- adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components).


  13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY


    Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.


  14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED


    ).

  15. OTHER INFORMATION


Vaccine against feline leukaemia.


The vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.


Plastic box containing:

10, 20 or 50 x 1 ml of vaccine. or

10, 20 or 50 x 0.5 ml of vaccine. Not all pack sizes may be marketed.